These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23006584)

  • 1. Are subtype differences important in HIV drug resistance?
    Lessells RJ; Katzenstein DK; de Oliveira T
    Curr Opin Virol; 2012 Oct; 2(5):636-43. PubMed ID: 23006584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 subtypes: epidemiology and significance for HIV management.
    Geretti AM
    Curr Opin Infect Dis; 2006 Feb; 19(1):1-7. PubMed ID: 16374210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.
    Chaplin B; Eisen G; Idoko J; Onwujekwe D; Idigbe E; Adewole I; Gashau W; Meloni S; Sarr AD; Sankalé JL; Ekong E; Murphy RL; Kanki P
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):71-80. PubMed ID: 20964479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotypic resistance tests for the management of the HIV-infected patient with non-B viral isolates.
    Visco-Comandini U; Balotta C
    Scand J Infect Dis Suppl; 2003; 106():75-8. PubMed ID: 15000590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultradeep sequencing of B and non-B HIV-1 subtypes: Viral diversity and drug resistance mutations before and after one month of antiretroviral therapy in naive patients.
    Epaulard O; Signori-Schmuck A; Larrat S; Kulkarni O; Blum MG; Fusillier K; Blanc M; Leclercq P; François O; Morand P
    J Clin Virol; 2017 Oct; 95():13-19. PubMed ID: 28830014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of HIV-1 pol diversity on drug resistance and its clinical implications.
    Kantor R
    Curr Opin Infect Dis; 2006 Dec; 19(6):594-606. PubMed ID: 17075337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug resistance in non-subtype B HIV-1.
    Kantor R; Katzenstein D
    J Clin Virol; 2004 Mar; 29(3):152-9. PubMed ID: 14962783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1.
    Richard N; Juntilla M; Abraha A; Demers K; Paxinos E; Galovich J; Petropoulos C; Whalen CC; Kyeyune F; Atwine D; Kityo C; Mugyenyi P; Arts EJ
    AIDS Res Hum Retroviruses; 2004 Apr; 20(4):355-64. PubMed ID: 15157354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China.
    Li Y; Gu L; Han Y; Xie J; Wang H; Lv W; Song X; Li Y; Iwamoto A; Ishida T; Li T;
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):289-97. PubMed ID: 25501612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes.
    Holguín A; Soriano V
    HIV Clin Trials; 2002; 3(5):403-11. PubMed ID: 12407490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.
    Kityo C; Thompson J; Nankya I; Hoppe A; Ndashimye E; Warambwa C; Mambule I; van Oosterhout JJ; Wools-Kaloustian K; Bertagnolio S; Easterbrook PJ; Mugyenyi P; Walker AS; Paton NI;
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):e45-e54. PubMed ID: 28129253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.
    Handema R; Terunuma H; Kasolo F; Kasai H; Sichone M; Yamashita A; Deng X; Mulundu G; Ichiyama K; Munkanta M; Yokota T; Wakasugi N; Tezuka F; Yamamoto N; Ito M
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):151-60. PubMed ID: 12643279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.
    Singh K; Flores JA; Kirby KA; Neogi U; Sonnerborg A; Hachiya A; Das K; Arnold E; McArthur C; Parniak M; Sarafianos SG
    Viruses; 2014 Sep; 6(9):3535-62. PubMed ID: 25254383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy.
    Brindeiro PA; Brindeiro RM; Mortensen C; Hertogs K; De Vroey V; Rubini NP; Sion FS; De Sá CA; Machado DM; Succi RC; Tanuri A
    J Clin Microbiol; 2002 Dec; 40(12):4512-9. PubMed ID: 12454144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase.
    Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA
    J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.
    Marconi VC; Sunpath H; Lu Z; Gordon M; Koranteng-Apeagyei K; Hampton J; Carpenter S; Giddy J; Ross D; Holst H; Losina E; Walker BD; Kuritzkes DR;
    Clin Infect Dis; 2008 May; 46(10):1589-97. PubMed ID: 18419495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-naïve persons in rural western Kenya.
    Onywera H; Maman D; Inzaule S; Auma E; Were K; Fredrick H; Owiti P; Opollo V; Etard JF; Mukui I; Kim AA; Zeh C
    PLoS One; 2017; 12(2):e0171124. PubMed ID: 28178281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characteristics of human immunodeficiency virus type 1 subtype C viruses from KwaZulu-Natal, South Africa: implications for vaccine and antiretroviral control strategies.
    Gordon M; De Oliveira T; Bishop K; Coovadia HM; Madurai L; Engelbrecht S; Janse van Rensburg E; Mosam A; Smith A; Cassol S
    J Virol; 2003 Feb; 77(4):2587-99. PubMed ID: 12551997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.